Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis

Qiaoli Yi; Jinwu Peng; Zhijie Xu; Qiuju Liang; Yuan Cai; Bi Peng; Qingchun He; Yuanliang Yan

doi:10.3389/fbioe.2022.806851

Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis

Front Bioeng Biotechnol. 2022 Jul 14:10:806851. doi: 10.3389/fbioe.2022.806851. eCollection 2022.

Authors

Qiaoli Yi¹, Jinwu Peng^{2

3}, Zhijie Xu^{2

3

4}, Qiuju Liang¹, Yuan Cai², Bi Peng², Qingchun He^{5

6}, Yuanliang Yan¹

Affiliations

¹ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
² Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
³ Department of Pathology, Xiangya Changde Hospital, Changde, China.
⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
⁵ Department of Emergency, Xiangya Hospital, Central South University, Changsha, China.
⁶ Department of Emergency, Xiangya Changde Hospital, Changde, China.

Abstract

B-Raf proto-oncogene serine/threonine-protein kinase (BRAF) is frequently altered in multiple cancer types, and BRAF V600 mutations act as a prime target for precision therapy. Although emerging evidence has investigated the role of BRAF, the comprehensive profiling of BRAF expression, alteration and clinical implications across various cancer types has not been reported. In this study, we used the TCGA dataset, covering 10,967 tumor samples across 32 cancer types, to analyze BRAF abnormal expression, DNA methylation, alterations (mutations and amplification/deletion), and their associations with patient survival. The results showed that BRAF expression, alteration frequency, mutation site distribution, and DNA methylation patterns varied tremendously among different cancer types. The expression of BRAF was found higher in PCPG and CHOL, and lower in TGCT and UCS compared to normal tissues. In terms of pathological stages, BRAF expression was significantly differentially expressed in COAD, KIRC, LUSC, and OV. The methylation levels of BRAF were significantly lower in LUSC, HNSC, and UCEC compared to normal tissue. The expression of BRAF and downstream gene (ETS2) was negatively correlated with methylation levels in various cancers. The overall somatic mutation frequency of BRAF was 7.7% for all cancer samples. Most fusion transcripts were found in THCA and SKCM with distinct fusion patterns. The majority of BRAF mutations were oncogenic and mainly distributed in the Pkinase_Tyr domain of THCA, SKCM, COADREAD, and LUAD. The BRAF mutations were divided into five levels according to the clinical targeted therapy implication. The results showed level 1 was mainly distributed in SKCM, COADREAD, and LUAD, while level 3B in THCA. The overall BRAF CNV frequency was about 42.7%, most of which was gain (75.9%), common in GBM, TGCT, and KIRP. In addition, the forest plot showed that increased BRAF expression was associated with poor patient overall survival in LIHC, OV, and UCEC. Taken together, this study provided a novel insight into the full alteration spectrum of BRAF and its implications for treatment and prognosis.

Keywords: BRAF; alteration; gene fusion; pan-cancer; prognosis.